News
CHMP recommends Idorsia’s dual acting treatment Quviviq for insomnia patients
The Committee for Medicinal Products for Human Use (CHMP) has recommended Quviviq (daridorexant) as the first dual orexin receptor antagonist in the EU for the treatment of adult patients with insomnia.